These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 18421047

  • 1. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.
    Yang L, Panetta JC, Cai X, Yang W, Pei D, Cheng C, Kornegay N, Pui CH, Relling MV.
    J Clin Oncol; 2008 Apr 20; 26(12):1932-9. PubMed ID: 18421047
    [Abstract] [Full Text] [Related]

  • 2. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Aricò M.
    J Clin Oncol; 2005 Oct 01; 23(28):7161-7. PubMed ID: 16192600
    [Abstract] [Full Text] [Related]

  • 3. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
    Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R.
    Thromb Haemost; 2008 Aug 01; 100(2):330-7. PubMed ID: 18690355
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.
    Hijiya N, Stewart CF, Zhou Y, Campana D, Coustan-Smith E, Rivera GK, Relling MV, Pui CH, Gajjar A.
    Cancer; 2008 May 01; 112(9):1983-91. PubMed ID: 18318429
    [Abstract] [Full Text] [Related]

  • 5. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.
    Kawedia JD, Liu C, Pei D, Cheng C, Fernandez CA, Howard SC, Campana D, Panetta JC, Bowman WP, Evans WE, Pui CH, Relling MV.
    Blood; 2012 Feb 16; 119(7):1658-64. PubMed ID: 22117041
    [Abstract] [Full Text] [Related]

  • 6. L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia.
    Baillargeon J, Langevin AM, Lewis M, Thomas PJ, Mullins J, Dugan J, Pollock BH.
    Cancer; 2005 Dec 15; 104(12):2858-61. PubMed ID: 16288492
    [Abstract] [Full Text] [Related]

  • 7. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
    Avramis IA, Panosyan EH, Dorey F, Holcenberg JS, Avramis VI, Children's Oncology Group.
    Clin Cancer Res; 2006 Dec 01; 12(23):6978-84. PubMed ID: 17145817
    [Abstract] [Full Text] [Related]

  • 8. [L-asparaginase-induced hyperlipidemia in a case of acute lymphoblastic leukemia].
    Konya H, Tamura S, Miyazaki E, Inoue N, Okamoto T, Takemoto Y, Kohsaki M, Kanemaru A, Kakishita E.
    Rinsho Ketsueki; 1991 Mar 01; 32(3):250-4. PubMed ID: 2041167
    [Abstract] [Full Text] [Related]

  • 9. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
    Zalewska-Szewczyk B, Andrzejewski W, Bodalski J.
    Pediatr Blood Cancer; 2004 Oct 01; 43(5):600-2. PubMed ID: 15382279
    [Abstract] [Full Text] [Related]

  • 10. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
    Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O.
    Pediatr Blood Cancer; 2010 May 01; 54(5):703-6. PubMed ID: 20063421
    [Abstract] [Full Text] [Related]

  • 11. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX, Cui YQ, Wu ZL, Ye TZ, Lai YH, Zou YW, Lu CY, Guan JM, Wei FG, Zhang H.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb 01; 26(2):100-2. PubMed ID: 15921627
    [Abstract] [Full Text] [Related]

  • 12. Anti-Erwinia asparaginase antibodies during treatment of childhood acute lymphoblastic leukemia and their relationship to outcome: a case-control study.
    Klug Albertsen B, Schmiegelow K, Schrøder H, Carlsen NT, Rosthøj S, Avramis VI, Jakobsen P.
    Cancer Chemother Pharmacol; 2002 Aug 01; 50(2):117-20. PubMed ID: 12172975
    [Abstract] [Full Text] [Related]

  • 13. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI, Martin-Aragon S, Avramis EV, Asselin BL.
    Anticancer Res; 2007 Aug 01; 27(4C):2561-72. PubMed ID: 17695416
    [Abstract] [Full Text] [Related]

  • 14. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M, Chevallier P, Delain M, Bulabois CE, Bologna S, Bernard M, Lafon I, Cornillon J, Maakaroun A, Tizon A, Padrazzi B, Ifrah N, Gruel Y, GOELAMS (Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang).
    Haematologica; 2008 Oct 01; 93(10):1488-94. PubMed ID: 18728028
    [Abstract] [Full Text] [Related]

  • 15. All dex'ed out with nowhere to go?
    Adamson PC, Barrett JS.
    J Clin Oncol; 2008 Apr 20; 26(12):1917-8. PubMed ID: 18421043
    [No Abstract] [Full Text] [Related]

  • 16. Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia.
    Evans WE, Rodman JH, Relling MV, Petros WP, Stewart CF, Pui CH, Rivera GK.
    J Pharmacol Exp Ther; 1992 Jan 20; 260(1):71-7. PubMed ID: 1731053
    [Abstract] [Full Text] [Related]

  • 17. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B, Kropshofer G, Klein-Franke A, Strasak AM, Hager J, Streif W.
    Pediatr Blood Cancer; 2008 Feb 20; 50(2):298-303. PubMed ID: 17443678
    [Abstract] [Full Text] [Related]

  • 18. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C, Citterio M, Zucchetti M, Conter V, Chiesa R, Colombini A, Malguzzi S, Silvestri D, D'Incalci M.
    Haematologica; 2006 Jan 20; 91(1):24-31. PubMed ID: 16434367
    [Abstract] [Full Text] [Related]

  • 19. Blood lipid profiles in children with acute lymphoblastic leukemia.
    Halton JM, Nazir DJ, McQueen MJ, Barr RD.
    Cancer; 1998 Jul 15; 83(2):379-84. PubMed ID: 9669823
    [Abstract] [Full Text] [Related]

  • 20. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A, Ohara A, Hasegawa D, Koh K, Saito T, Kiyokawa N, Kikuchi A, Takahashi H, Ikuta K, Hayashi Y, Hanada R, Tsuchida M, Tokyo Children's Cancer Study Group.
    Haematologica; 2008 Aug 15; 93(8):1155-60. PubMed ID: 18519521
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.